Nilsson Peter M
Skane University Hospital, Lund University, Malmö, Sweden.
Front Cardiovasc Med. 2020 Feb 4;7:6. doi: 10.3389/fcvm.2020.00006. eCollection 2020.
With increasing age, the cardiovascular risk increases, as does frailty, with negative health consequences such as coronary disease, stroke, and vascular dementia. However, this aging process seems to take a more rapid course in some individuals, as reflected in the Early Vascular Aging (EVA) syndrome that over the recent 10 years has attracted increased attention. The core of the EVA syndrome is arterial stiffness in the media layer of large elastic arteries, a process that can be measured by pulse wave velocity, for example, along the aorta. Hypertension is a well-known cardiovascular risk factor in its own right, but also linked to the EVA process. However, several studies have shown that non-hemodynamic factors also contribute to arterial stiffness and EVA, such as impaired glucose metabolism, chronic inflammation, and oxidative stress. New perspectives have been introduced for linking early life programming affecting new-born babies and birth weight, with a later risk of hypertension, arterial stiffness and EVA. New drugs are being developed to treat EVA when lifestyle intervention and conventional risk factor controlling drugs are not enough. Finally, the opposite phenotype of EVA is Healthy Vascular Aging (HVA) or even Super Normal Vascular Aging (SUPERNOVA). If protective mechanisms can be found and mapped in these fortunate subjects with a slower than expected aging process, there could exist a potential to find new drug targets for preventive therapy.
随着年龄的增长,心血管风险增加,身体虚弱的情况也会增加,并会带来诸如冠心病、中风和血管性痴呆等负面健康后果。然而,在某些个体中,这种衰老过程似乎进展得更快,这在早期血管衰老(EVA)综合征中有所体现,在最近十年中,该综合征已引起越来越多的关注。EVA综合征的核心是大弹性动脉中层的动脉僵硬,这一过程可以通过例如沿主动脉的脉搏波速度来测量。高血压本身就是一个众所周知的心血管危险因素,而且还与EVA过程有关。然而,几项研究表明,非血液动力学因素也会导致动脉僵硬和EVA,如糖代谢受损、慢性炎症和氧化应激。对于将影响新生儿和出生体重的早期生命编程与后期患高血压、动脉僵硬和EVA的风险联系起来,已经有了新的观点。当生活方式干预和传统危险因素控制药物不足时,正在研发新药来治疗EVA。最后,EVA的相反表型是健康血管衰老(HVA)甚至超正常血管衰老(SUPERNOVA)。如果能在这些衰老过程比预期慢的幸运个体中找到并明确其保护机制,那么就有可能找到预防性治疗的新药物靶点。